The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
OPTIMIZE-1 primary analysis: Safety, efficacy and biomarker results of a phase 1b/2 study combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
 
Jean-Luc Van Laethem
No Relationships to Disclose
 
Ivan Borbath
Honoraria - AstraZeneca; Eisai; Ipsen; Roche/Genentech (Inst); SERVIER (Inst)
Consulting or Advisory Role - Lilly (Inst)
Research Funding - SERVIER (Inst)
Travel, Accommodations, Expenses - Ipsen (Inst)
 
Karen Paula Geboes
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Ipsen (Inst); SERVIER (Inst)
Speakers' Bureau - Bristol-Myers Squibb (Inst); Ipsen (Inst)
Expert Testimony - SERVIER (Inst)
Travel, Accommodations, Expenses - SERVIER (Inst)
 
Philippe Alexandre Cassier
Consulting or Advisory Role - Boehringer Ingelheim; Brenus Pharma; Bristol-Myers Squibb/Celgene; OSE Immunotherapeutics; Scenic Biotech
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); Alligator Bioscience (Inst); Amgen (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Daiichi Sankyo/UCB Japan (Inst); Debiopharm Group (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Molecular Partners (Inst); Novartis (Inst); OSE Immunotherapeutics (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Roche/Genentech (Inst); Sotio (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Novartis; OSE Immunotherapeutics; Roche
(OPTIONAL) Uncompensated Relationships - ReACT Therapeutics
 
Aurélien Lambert
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca/MedImmune; Bayer; GlaxoSmithKline; Ipsen; Janssen; Merck KGaA; Merck Serono; Novartis; Pierre Fabre; Servier/Pfizer
Travel, Accommodations, Expenses - Merck KGaA; Pfizer
 
Emmanuel Mitry
Honoraria - AstraZeneca/Daiichi Sankyo; Bayer; Esteve; MSD; Pierre Fabre; SERVIER; Viatris
Travel, Accommodations, Expenses - MSD; Pierre Fabre
 
Hans Prenen
Honoraria - Amgen; AstraZeneca; Merck; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Biocartis; cureteq
 
Lorenzo Pilla
Employment - Pierre Fabre (I)
 
Jean-Frédéric Blanc
Honoraria - AstraZeneca; Bayer Schering Pharma; Eisai; INCYTE; IPSEN; Roche; SERVIER
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; IPSEN; ROCHE; SERVIER; Taiho Pharmaceutical; Taiho Pharmaceutical
Travel, Accommodations, Expenses - AstraZeneca; IPSEN; Roche
 
Inmaculada Gallego Jiménez
No Relationships to Disclose
 
Roberto A. Pazo Cid
Consulting or Advisory Role - Astellas Pharma; AstraZeneca Spain; Bristol-Myers Squibb/Celgene; Eisai Europe; Ipsen; Roche; SERVIER
Speakers' Bureau - Astellas Pharma; AstraZeneca Spain; BMS GmbH & Co. KG; SERVIER
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Lilly; Roche/Genentech
 
Mercedes Rodríguez Garrote
Honoraria - SERVIER
 
Jaime Feliú
Consulting or Advisory Role - Amgen; AstraZeneca; Roche/Genentech; Viatris
Research Funding - Amgen; Amgen
Travel, Accommodations, Expenses - Amgen
 
Karin Nordbladh
Employment - Alligator Biosence AB
Stock and Other Ownership Interests - Alligator Bioscience
Patents, Royalties, Other Intellectual Property - Listed as one of the inventors for combination treatment in development at Alligator Bioscience. Patent reference: WO2023247660A1
 
Karin Enell Smith
Employment - Alligator Bioscience
Stock and Other Ownership Interests - Alligator Bioscience
Patents, Royalties, Other Intellectual Property - Inventor "Novel Combination Therapies and Uses Thereof" Inventor "Anti-Cd40 Human Antibodies" Inventor "Novel Anti-Cd137 Antibodies and Uses Thereof"
 
David Gomez Jimenez
Employment - Alligator Bioscience
Stock and Other Ownership Interests - Pfizer
Research Funding - Alligator Bioscience; Asgard therapeutics
Patents, Royalties, Other Intellectual Property - Title: Combination therapy PCT application number: PCT/EP2023/066889 (Inst)
Travel, Accommodations, Expenses - Alligator Bioscience
 
Peter Ellmark
Employment - Alligator Bioscience
Leadership - Alligator Bioscience
Stock and Other Ownership Interests - Alligator Bioscience
Patents, Royalties, Other Intellectual Property - Inventor on patents assigned to Alligator Bioscience
 
Yago Pico de Coaña
Employment - Alligator Bioscience
Stock and Other Ownership Interests - Alligator Bioscience
Patents, Royalties, Other Intellectual Property - Inventor on patents assigned to Alligator Bioscience
Travel, Accommodations, Expenses - Alligator Bioscience
 
Sumeet Vijay Ambarkhane
Employment - Alligator Bioscience; MorphoSys
Leadership - Alligator Bioscience
Stock and Other Ownership Interests - Alligator Bioscience; MorphoSys
Patents, Royalties, Other Intellectual Property - Patent under review
Travel, Accommodations, Expenses - Alligator Bioscience; MorphoSys
 
Teresa Macarulla
Consulting or Advisory Role - Ability Pharma; Advance Medical; Amgen; Aptitude Health; Arcus Biosciences; AstraZeneca; Basilea; Baxter; BioLineRX; Celgene; Eisai; Ellipses Pharma; Esteve; Incyte; Ipsen; Janssen; Janssen; Lilly; Medscape; MFAR, Marketing Farmacéutico & Investigación Clínica; MSD; Novocure; Paraxel; Prime Oncology; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Zymeworks
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Agios (Inst); Amc Medical Research (Inst); Amgen (Inst); Armo Biosciences (Inst); ASLAN Pharmaceuticals (Inst); ASTRAZENECA (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Beigene (Inst); BiolineRx (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (BMS) (Inst); Cantargia AB (Inst); Celgene (Inst); Eisai (Inst); ERYTECH Pharma (Inst); Fibrogen (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Incyte (Inst); Ipsen (Inst); Keralty Group (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Millennium (Inst); Nelum Corp. (Inst); Novartis (Inst); Novocure (Inst); OncoMed (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Roche (Inst); VCN Biosciences (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER